Amicus Therapeutics to Present at Cowen and Company 34th Annual Health Care Conference

Amicus Therapeutics to Present at Cowen and Company 34th Annual Health Care Conference  CRANBURY, N.J., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Cowen and Company 34^th Annual Health Care Conference on Tuesday, March 4, 2014 at 10:00 a.m. ET.  A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.   About Amicus Therapeutics  Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.  FOLD-G  CONTACT: Amicus Therapeutics          Sara Pellegrino          (609) 662-5044          spellegrino@amicusrx.com